Arcus Biosciences, Inc. logo

Arcus Biosciences, Inc.

Arcus Biosciences (NYSE:RCUS), is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcuss lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.

Arcus has several programs, including a dual adenosine receptor antagonist and an anti-PD-1 antibody (both are in Phase 1 trials), as well as a small molecule inhibitor of CD73 and an anti-TIGIT antibody, which are in IND-enabling studies.

Arcus Bioscience Key Team comprises of highly experienced veterns from their earlier company Flexus Biosciences (acquired in 2015 by BMS in $1.2 Bn USD).

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”RCUS” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.arcusbio.com
Founded2015
Disease Focus
Development StageClinical
STOCK CODENYSE: RCUS
Address
3928 Point Eden Way, CA 94545
Hayward
United States
Email
info@arcusbio.com
Contact Number
+1 510-694-6200

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/arcus-biosciences” connections=”true” suffix=””]

Pipeline

AB928 is a small-molecule and selective dual antagonist of A2aR and A2bR adenosine receptors, which are expressed on the surface of immune cells and mediate the immunosuppressive effects of adenosine. It is the only drug currently in development, which block both of these adenosine receptors.

AB122 potently and selectively blocks this interaction between PD-1 and its ligands, and is currently in a Phase 1 trial in cancer patients and is also in Phase 1/2 clinical evaluation in combination with AB928 from the second quarter of 2018.

AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment and is the only small-molecule CD73 inhibitor currently in development.

AB154 is a mAb that potently and selectively blocks a novel immune checkpoint called TIGIT. Like some of the first-generation immune checkpoints (e.g., PD-1 and CTLA-4), TIGIT is expressed on exhausted T cells, which may reside inside tumors but are unable to mount an effective attack against the cancer cells.

In Dec 2017, Arcus granted Taiho Pharmaceutical, access to its development candidates in Japan and certain other territories in Asia (excluding China). Under the terms, Arcus will receive $35 Mn during the first three years of the agreement. In return, TAIHO will receive an option to in-license the development and commercialization rights in its region to clinical stage product candidates from Arcuss portfolio over a five-year term. For any product candidate for which TAIHO exercises a license, Arcus will receive an option payment and is eligible to receive up to $275 Mn in development, regulatory and commercial milestone payments per molecule. Arcus is also eligible to receive royalties on the net sales of each product candidate that TAIHO commercializes in its region ranging from the high single digits to mid-double digits.

In Mar 2018, Arcus Biosciences (NYSE: RCUS), raised 120 Mn through its initial public offering. Earlier, in Nov 2017, raised $107 Mn in Series C financing and has raised $227 Mn in total equity capital since its inception. Key investors included Taiho Ventures, GV, Invus, DROIA Oncology Ventures, Stanford University, The Column Group, Foresite Capital, Novartis and Celgene.

In May 2015, Arcus Biosciences raised $49.7 Mn in Series A round of funding, led by family and friends of company founders and participated by The Column Group (TCG), Foresite Capital, Novartis and Celgene.